



**SOLVE  
ON.**

## **Incyte Reaffirms Commitment to Delaware Community by Opening New Research Facility and Extending the Incyte Cancer Care Assistance Fund for Delaware**

**WILMINGTON, Del. – April 4, 2022** – Today at a celebration for the opening of a new state-of-the-art research facility at its Wilmington, DE, headquarters, Incyte announced a five-year extension of the Incyte Cancer Care Assistance Fund for Delaware beginning in 2023. The Fund, which is fully administered by the Cancer Support Community Delaware (CSCDE), has provided emergency financial assistance for Delaware cancer patients, their caregivers and family members since its inception in 2018.

Incyte has committed to doubling its annual contribution to the Fund and will now provide up to \$200,000 each year through the Incyte Charitable Giving Foundation. To date, the Fund has provided assistance to 435 people with different types of cancer, with an average expenditure of \$1,175 per person. Additional details about the Fund, including how to apply for assistance, can be found [here](#).

“We are very pleased to extend the Incyte Cancer Care Assistance Fund for Delaware and are proud to continue this important work with the CSCDE,” said Paula Swain, Executive Vice President of Human Resources and Chair of The Incyte Charitable Giving Foundation. “Today, as we also celebrate the opening of a new research facility at our headquarters in Wilmington, we reaffirm our commitment to Delaware and to addressing the needs of patients with cancer and other serious diseases both locally and around the world.”

“On behalf of CSCDE, and the patients, caregivers and families of Delaware, we are grateful to not only be able to provide emotional and physical assistance but much needed financial support through the Incyte Cancer Care Assistance Fund which helps to lessen the burden of a cancer diagnosis,” said Nicole Topkis Pickles, Executive Director, Cancer Support Community Delaware.

Regarding Incyte’s new facility – which includes four floors of lab space – at capacity it will house over 440 employees primarily focused on research and clinical development. Today, Incyte employs over 2,000 people across North America, Europe and Asia, with approximately 1,000 people based in the greater Wilmington area.

### **About Cancer Support Community Delaware (CSCDE)**

The mission of Cancer Support Community Delaware is to ensure that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. Through participation in professionally led support groups, educational workshops and mind/body classes, people affected by cancer learn vital skills that enable them to regain control, reduce isolation and restore hope regardless of the stage of disease. At Cancer Support Community Delaware, all programs are at no cost to cancer

patients, caregivers and family members. More information about Cancer Support Community Delaware is available at [www.cancersupportdelaware.org](http://www.cancersupportdelaware.org).

### **About the Incyte Charitable Giving Foundation**

The Incyte Charitable Giving Foundation, part of Incyte Involved, the Company's philanthropic and employee and community engagement program, provides charitable donations to publicly funded 501(c) (3) tax-exempt nonprofit organizations specifically serving the needs of communities in Delaware focused on two areas—Oncology Patient Support and Resources and Community Partnerships.

More information regarding Incyte Involved and the Incyte Charitable Giving Foundation, including the application process, funding guidelines, important information for applicants and quarterly submissions calendar, can be found [here](#).

### **About Incyte**

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](http://Incyte.com) and follow [@Incyte](#).

# # #

### **Contacts:**

#### **Media**

Catalina Loveman      +1 302 498 6171  
[cloveman@incyte.com](mailto:cloveman@incyte.com)